Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions

International Journal of Cancer

Volumn 123, Issue 10, 2008, Pages 2267-2278

  Liao, Jinhui ^a   Li, Xin ^a   Koh, Amy J ^a   Berry, Janice E ^a   Thudi, Nanda ^b   Rosol, Thomas J ^b   Pienta, Kenneth J ^c,d   McCauley, Laurie K ^a,d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Parathyroid hormone related protein; Prostate carcinoma; PTHrP; Skeletal metastasis

Indexed keywords

COMPLEMENTARY DNA; PARATHYROID HORMONE RELATED PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE LESION; BONE MARROW CELL; BONE MASS; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; IN VITRO STUDY; MALE; MICROENVIRONMENT; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOBLAST; OSTEOBLASTOMA; OSTEOCLAST; PARATHYROID GLAND; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; STROMA CELL; WESTERN BLOTTING; ANIMAL; BONE TUMOR; CELL DIVISION; DOG; METASTASIS; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; DOGS; MALE; MICE; PARATHYROID HORMONE-RELATED PROTEIN; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RATS;

EID: 53449091768     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23602     Document Type: Article

References (53)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
4. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res 1998;4:1765-72.
5. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-53.
6. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146:1727-36.
7. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 2005;65:8818-25.
8. Clezardin P, Ebetina FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4.
9. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005;31 (Suppl 3):19-25.
10. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005;23:8219-24.
11. Liao J, Schneider A, Datta NS, McCauley LK. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006;66:9065-73.
12. Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, Scadden DT. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 2006;439:599-603.
13. Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Butters RR, Brown EM. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 2000;141:4357-64.
14. Liao J, McCauley LK. Skeletal metastasis: established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 2006;25:559-71.
15. Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005;327:468-72.
16. Hoey RP, Sanderson C, Iddon J, Brady G, Bundred NJ, Anderson NG. The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer 2003;88:567-73.
17. Cataisson C, Lieberherr M, Cros M, Gauville C, Graulet AM, Cotton J, Calvo F, de Vernejoul MC, Foley J, Bouizar Z. Parathyroid hormone-related peptide stimulates proliferation of highly tumorigenic human SV40-immortalized breast epithelial cells. J Bone Miner Res 2000;15:2129-39.
18. Massfelder T, Lang H, Schordan E, Lindner V, Rothhut S, Welsch S, Simon-Assmann P, Barthelmebs M, Jacqmin D, Helwig JJ. Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene. Cancer Res 2004;64:180-8.
19. Shen X, Falzon M. PTH-related protein enhances LoVo colon cancer cell proliferation, adhesion, and integrin expression. Regul Pept 2005;125:17-27.
20. Shen X, Falzon M. PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol Cell Endocrinol 2003;199:165-77.
21. Hastings RH, Araiza F, Burton DW, Zhang L, Bedley M, Deftos LJ. Parathyroid hormone-related protein ameliorates death receptor-mediated apoptosis in lung cancer cells. Am J Physiol Cell Physiol 2003;285:C1429-C1436.
22. Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001;142:4047-54.
23. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 2007;282:33098-106.
24. Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, Sims NA. Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci 2006;1068:458-70.
25. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8.
26. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-8.
27. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554-60.
28. LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-Gregg SH, van Bokhoven A, Davis D, Corn S, Rosol TJ. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 2006;66:1213-22.
29. Dougherty KM, Blomme EA, Koh AJ, Henderson JE, Pienta KJ, Rosol TJ, McCauley LK. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999;59:6015-22.
30. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006;442:779-85.
31. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 2005;146:4584-96.
32. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, Rowley DR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005;65:8887-95.
33. Pettway GJ, Schneider A, Koh AJ, Widjaja E, Morris MD, Meganck JA, Goldstein SA, McCauley LK. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone 2005;36:959-70.
34. Chen TL. Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment. Bone 2004;35:83-95.
35. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, Polverini PJ, Nor J, Kitajewski J, Wang CY. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8:13-23.
36. Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK. Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 2007;22:951-64.
37. Isales CM, Sumpio B, Bollag RJ, Zhong Q, Ding KH, Du W, Rodriguez-Commes J, Lopez R, Rosales OR, Gasalla-Herraiz J, McCarthy R, Barrett PQ. Functional parathyroid hormone receptors are present in an umbilical vein endothelial cell line. Am J Physiol Endocrinol Metab 2000;279:E654-E662.
38. Rian E, Jemtland R, Olstad OK, Endresen MJ, Grasser WA, Thiede MA, Henriksen T, Bucht E, Gautvik KM. Parathyroid hormone-related protein is produced by cultured endothelial cells: a possible role in angiogenesis. Biochem Biophys Res Commun 1994;198:740-7.
39. McKee RL, Goldman ME, Caulfield MP, DeHaven PA, Levy JJ, Nutt RF, Rosenblatt M. The 7-34-fragment of human hypercalcemia factor is a partial agonist/antagonist for parathyroid hormone-stimulated cAMP production. Endocrinology 1988;122:3008-10.
40. Bryden AA, Hoyland JA, Freemont AJ, Clarke NW, George NJ. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer 2002;86:322-325.
41. Iguchi H, Tanaka S, Ozawa Y, Kashiwakuma T, Kimura T, Hiraga T, Ozawa H, Kono A. An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res 1996;56:4040-3.
42. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
43. Guise TA, Yin JJ, Thomas RJ, Dallas M, Cui Y, Gillespie MT. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 2002;30:670-6.
44. Thudi NK, Nadella PMV, Rosol TJ. Modulation of osteoblastic activity by the canine prostate cancer cells. Skeletal complications of malignancy V (meeting abstract) p 90, 2007.
45. Aubin JE, Liu F, Malaval L, Gupta AK. Osteoblast and chondroblast differentiation. Bone 1995;17:77S-83S.
46. Zetter BR. Angiogenesis and tumor metastasis. Ann Rev Med 1998;49:407-24.
47. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, Lindblom P, Shani M, Zicha D, Adams RH. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 2006;124:161-73.
48. Funk JL, Wei H, Downey KJ, Yocum D, Benjamin JB, Carley W. Expression of PTHrP and its cognate receptor in the rheumatoid synovial microcirculation. BiochemBiophys Res Commun 2002;297:890-7.
49. Bakre MM, Zhu Y, Yin H, Burton DW, Terkeltaub R, Deftos LJ, Varner JA. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med 2002;8:995-1003.
50. Diamond AG, Gonterman RM, Anderson AL, Menon K, Offutt CD, Weaver CH, Philbrick WM, Foley J. Parathyroid hormone hormone-related protein and the PTH receptor regulate angiogenesis of the skin. J Invest Dermatol 2006;126:2127-34.
51. Akino K, Ohtsuru A, Kanda K, Yasuda A, Yamamoto T, Akino Y, Naito S, Kurokawa M, Iwahori N, Yamashita S. Parathyroid hormone-related peptide is a potent tumor angiogenic factor. Endocrinology 2000;141:4313-16.
52. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A, Takigawa M. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 2006;21:1045-59.
53. Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, Bouxsein ML, Faugere MC, Guldberg RE, Gerstenfeld LC, Haase VH, Johnson RS, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007;117:1616-26.